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Abstract
Fibroblast growth factor receptor 3 (FGFR3) and P53 mutations are
frequently observed in bladder cancer. We here describe the distribution
of FGFR3 mutations and P53 overexpression in 260 primary urothelial
cell carcinomas. FGFR3 mutations were observed in 59% and P53 over-
expression in 25%. Interestingly, FGFR3 and P53 alterations were mutu-
ally exclusive, because they coincided in only 5.7% of tumors. Conse-
quently, we propose that they characterize two alternative genetic
pathways in urothelial cell carcinoma pathogenesis. The genetic alter-
ations were reflected in the pathology and the clinical outcome, i.e.,
FGFR3 mutations were found in low-stage/-grade tumors and were asso-
ciated with a favorable disease course, whereas P53 alterations were tied
to adverse disease parameters.
Introduction
Urothelial cell carcinoma (UCC), of which bladder cancer is the
major representative, is the fifth most common malignancy in
Western society (1). Because of its frequent recurrence and the
relatively long life span of patients, UCC is the most expensive
cancer in health care (2). Approximately 70% of the patients
initially present with superficial tumors (stages pTa, pT1, or pTis).
UCCs fall into two major groups with a substantially different
natural behavior, i.e., superficial and invasive UCC. More than
80% of superficial UCCs remain confined to the submucosa
throughout their clinical course, whereas most of the invasive
UCCs exhibit their invasive property at first presentation, and
these tumors are associated with a high propensity to metastasize
(3). In the last decade, many efforts were undertaken to find a
molecular basis for this divergent disease pathogenesis of UCC.
Mutations in the P53 gene were frequently found in invasive UCC
as well as in high-grade superficial UCC including carcinoma in
situ, the putative precursor of invasive UCC, whereas these muta-
tions were rare in well-differentiated superficial UCC (4, 5). On
the other hand, loss(es) of heterozygosity (LOH) on the chromo-
somal arms 9p and 9q was the most frequent genetic alteration in
the low-grade papillary lesions (4, 5). However, subsequent studies
showed that LOH on 9p/q was also a very common finding in
high-grade superficial and invasive UCC (6 –9). Consequently,
LOH on 9p/q did not provide a sufficient molecular explanation for
the clinically divergent disease pathogenesis of UCC. Recently,
fibroblast growth factor receptor 3 (FGFR3) mutations, identical
to the mutations responsible for several skeletal anomalies associ-
ated with dwarfism in most cases, were reported at a high fre-
quency in UCC and at a low frequency in multiple myeloma and
cervical cancer (10 –12). Surprisingly, the oncogenic FGFR3 mu-
tations were particularly related to favorable UCCs in three pilot
studies (13–15). The FGFR3 mutations occur predominantly in
UCC (11, 12), whereas P53 mutations are found in over 50% of
human cancers. In the present study, we investigated the distribu-
tion of FGFR3 and P53 alterations in 260 primary (first diagnosis)
UCCs. We here report that FGFR3 and P53 characterize almost
80% of UCCs and that these mutations seem to exclude each other.
These distinct molecular features were also reflected in the differ-
ent pathological parameters and the clinical follow-up of the pa-
tients. We, therefore, propose that FGFR3 and P53 characterize
different pathogenesis pathways for UCC.
Materials and Methods
Patients and Tumor Samples. We analyzed the tumors of 260 patients
(196 males) with first diagnosis UCC. The median age of the patients was 67.2
years. No patient had a hereditary skeletal anomaly. A paraffin-embedded,
formalin-fixed tissue block was obtained from the archives of two pathology
departments (Erasmus MC and Sint Franciscus Gasthuis, Rotterdam, the
Netherlands) and was classified according to the TNM and WHO guidelines.
A single pathologist (T.H. v. d. K.) reviewed the slides using the 1998 WHO/
International Society of Urological Pathology classification system for grad-
ing. In case of multifocality (n  67), the lesion with the highest grade/stage
was taken. The largest tumor was taken if grade/stage were the same for
multiple UCCs.
P53 Analysis. Four-m-thick sections were freshly cut from each tissue
block and mounted on amino alkylsilane-coated slides. Incubation with pri-
mary antibody P53 (clone DO-7; DAKO, Glostrup, Denmark; dilution, 1:200)
was 30 min in PBS/BSA 5%. Positive and negative controls were included.
The conventional avidin-biotin complex method was applied for all immuno-
stainings. Two persons (B. W. G. v. R. and A. N. V.) independently assessed
the slides without knowledge of clinical data. In case of heterogeneity, the
parts within the tumor that showed the highest positive:total ratio were par-
ticularly assessed. This was performed if these regions comprised at least 10%
of the tumor load in the examined tissue section. P53 overexpression was
scored if10% stained positive. In case of discrepancy between the observers,
the slides were reassessed in a combined session without the information of the
previous scores.
FGFR3 Analysis. Standard H&E slides served as templates for manual
microdissection. The dissected samples contained a minimum of 70% tumor
cells. DNA was extracted using the DNeasy Tissue kit (Qiagen GmbH, Hilden,
Germany). FGFR3 mutation analysis was by PCR single-strand conformation
polymorphism analysis (14), followed by sequencing in case of a shift (T7
Sequenase v2.0; Amersham life Science, Inc., Cleveland, OH). DNA extracted
from venous blood was available from 139 patients. Mutation analyses were
performed without knowledge of clinical data.
Clinical Follow-Up and Statistical Analysis. The follow-up data were
collected by chart review. Disease-specific survival was determined. The
patients were censored at their last clinical visit or at the time of their death.
The statistical package for social sciences 9.0 (SPSS Inc., Chicago, IL)
computer software was used for the data documentation and analysis. The
two-sided Fisher’s exact test was used to analyze the relationships between the
molecular variables and their correlation with pathological stage and grade.
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The clinical outcome was analyzed by applying the Kaplan-Meier method.
Statistical significance was assumed if P  0.05.
Results
Mutations in the P53 and FGFR3 genes were studied in 260
primary UCCs. Activating FGFR3 mutations were found in 153
(59%) of these tumors. We found 117, 32, and 4 mutations in the
exons 7 (R248C and S249C), 10 (G372C, Y375C, and A393E), and
15 (K652T, K652E, and K652M), respectively. No mutations were
detected in exon 19. No mutations were seen in the matched blood
samples. P53 overexpression, presumably reflecting missense muta-
tions in the P53 gene, was noted in 66 (25%) cases. Table 1 shows a
highly significant inverse relation between the presence of a FGFR3
mutation and P53 overexpression (P 0.0001). Only 5.7% of the 260
primary UCCs were positive for both markers, whereas 72.7% UCCs
were either positive for FGFR3 or positive for P53.
We subsequently determined the correlation of FGFR3 and P53
with pathological stage and grade for the 260 UCCs. FGFR3 muta-
tions were found in 77% of pTa, 31% pT1, and 15% pT2 tumors.
Conversely, P53 overexpression was found in 11% pTa, 51% pT1,
and 56% pT2 tumors, respectively (P  0.0001). The numbers for
pathological grade showed the same trend. FGFR3 mutations were
found in 85% of urothelial neoplasia of low malignant potential
(LMP), in 71% of low-grade (LG) and in 26% of high-grade (HG)
cases. On the other hand, P53 overexpression was found in only 1%
of LMP, in 15% of LG and in 54% of HG cases, respectively
(P  0.0001). The distributions of the stages and grades for the
FGFR3/P53 subgroups are given in Fig. 1. In general, the FGFR3
mutation related to favorable, i.e., pTa and LMP/LG disease, whereas
P53 overexpression indicated unfavorable, i.e., invasive and HG dis-
ease.
The UCCs, which were wild type for both genes, the so-called
double negatives, were a substantial subgroup encompassing 21% of
the 260 UCCs (Table 1). When compared with stage and grade, these
UCCs apparently included tumors of all grades and stages, with a
higher percentage of pTa tumors than the P53-positive subgroup, i.e.,
51% versus 22%, but also a higher percentage high-grade tumors than
the FGFR3-mutation subgroup, i.e., 48% versus 12% (Fig. 1).
Besides histopathological parameters, the clinical outcome of the
260 patients was also determined. The mean follow-up was 5.6 years
(SD, 3.7 years). Twenty-one patients died of UCC. The Kaplan-Meier
analyses in Fig. 2 clearly show that patients with a FGFR3 mutation
in their UCC have a favorable prognosis, whereas patients with P53
overexpression have a worse prognosis than patients with a normal
P53 expression pattern.
Discussion
UCCs are genetically characterized by frequent LOH; mutations
and deletions in the P53, RB and p16 tumor suppressor genes; and
activating point mutations in the gene for the FGFR3 receptor, LOH
of chromosomal arms 9p and 9q is observed in over 50% of UCC.
Homozygous deletions of the p16 cyclin-dependent kinase inhibitor
are found in 20–30% of high-grade and -stage tumors (16). Bladder tumors with pRB alterations are significantly more prone to metasta-
size (Ref. 17, and references therein). Mutations in the P53 gene are
observed in poorly differentiated carcinomas, and mutations in this
gene apparently characterize tumors with a worse prognosis. On the
basis of these observations Spruck et al. (5), proposed a two-pathway
model for UCC pathogenesis, in which P53 mutations delineated one
arm of the pathway. LOH on chromosome 9 was supposed to char-
acterize the other arm. However, later work revealed that chromosome
9 loss is found in all grades and stages and, therefore, can no longer
serve as a marker for the noninvasive pathway (6–9). A recent update
Fig. 2. Kaplan-Meier analyses for disease specific-survival. The survival plots (log-
rank) for FGFR3 (P  0.0001) and P53 (P  0.0011) are shown. The dashed lines, the
follow-up of patients with a FGFR3 mutation and P53 overexpression, respectively. mt,
mutant; wt, wild-type.
Table 1 Inverse relationship between FGFR3a mutations and P53 overexpression in
urothelial cell carcinoma (P  0.0001)
A P53 mutation was assumed if 10% of the cells stained positive.
FGFR3 wt FGFR3 mt
P53 wt 56 138
P53 mt 51 15
Total 107 153
a FGFR3, fibroblast growth factor receptor 3; wt, wild type; mt, mutated type.
Fig. 1. The relationship for FGFR3/P53 subgroups with pathological stage (top panel)
and grade (bottom panel). The stage distribution was 171 pTa, 55 pT1, and 27 pT2 , and
5 pT3, and 2 pT4 lesions. The correlation between mutations in the FGFR3 gene with pTa
and low-grade [low malignant potential (LMP) and low-grade urothelial carcinoma (LG)]
tumors is notable. Conversely, P53 overexpression, presumably caused by missense
mutations, was associated with invasive (pT1) and high-grade (HG) disease. The tumors
that were wild type (wt) for both genes represent a group in which all stages and grades
are found. FGFR3-mt, FGFR3-mutant tumors; FGFR3wt, FGFR3-wild-type tumors;
P53wt, P53-wild-type tumors; P53mt, P53-mutant tumors
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of the UCC pathogenesis model, including more markers, was pub-
lished by Cote and Datar (17). However, although many genes may
play a role in UCC pathogenesis, most of them are only mutated in a
limited percentage of tumors and, at present, their mutual dependen-
cies, when present, are not entirely clear.
We have recently shown that FGFR3 mutations are generally
associated with favorable disease characteristics such as low stage and
grade, low recurrence rate, and a better prognosis (13, 18). In the
present study, we intended to place this new genetic marker in the
genetic pathogenesis model for UCC. To this end, we determined
the FGFR3 and P53 status in 260 primary tumors. To our surprise, we
observed that alterations in FGFR3 and P53 were almost always
mutually exclusive. Together these two markers described 79% of the
primary UCC. However, they concurred in only 5.7%. This suggested
that FGFR3 and P53 characterize two distinct genetic pathways in
UCC pathogenesis. While this paper was being reviewed, Bakkar et
al. (19) reported similar findings based on a study of 81 patients. In
our patients, the FGFR3 mutation was associated with pTa and
LMP/LG tumors, whereas the P53 marked invasive and HG carcino-
mas. In addition, the clinical outcome of the two investigated molec-
ular markers confirmed this suggestion of two genetic pathways. A
model for UCC pathogenesis based on our observations is given in
Fig. 3. This model resembles Spruck’s original model [Spruck et al.
5)], but clearly designates two distinct pathways with genetic markers
for a noninvasive and papillary, FGFR3-associated pathway and an
invasive P53-associated pathway. Together, these two markers pro-
vided a genetic framework for the majority of UCCs. The addition of
the FGFR3 marker significantly expands Spruck’s original model
[most recently reviewed in Cote and Datar (17)]. We feel that, at the
moment, it is not completely clear where to put LOH, especially of
chromosome 9q, in this pathway. In P53-positive tumors, this event
may have occurred before the P53 mutation. However, in a consid-
erable percentage of FGFR3-mutant tumors, LOH may occur after the
FGFR3 mutation, because FGFR3 mutations are more frequent than
LOH of 9q. On the other hand, we previously showed, in evolutionary
tree models of multiple UCC recurrences, that tumors with LOH of 9q
can precede recurrences with a mutation in the FGFR3 gene (7). Thus,
the FGFR3 mutation is not necessarily the first genetic event in
superficial tumor formation. In the model displayed here, we also
suggest that UCC with alterations in both FGFR3 and P53 derive
from FGFR3-mutant tumors. We argued that it would be more diffi-
cult for a P53-positive, invasive, HG carcinoma to become a lower-
grade superficial tumor than that a pTa, LMP/LG tumor would trans-
form into a more invasive, higher-grade descendant. This small group
of UCCs apparently displays an intermediate phenotype when com-
pared with the tumors with single alterations (Ref. 18 and present
study). Thus, it appears that the effect of the FGFR3 mutation miti-
gates the effect of the P53 mutation. The remainder of UCCs, 21% in
our series, lacking P53 or FGFR3 alterations, forms an interesting
subset. The fact these tumors include all possible grades and stages
suggests that they may also harbor different genotypes. Some of these
tumors may in the future, perhaps, be placed in a FGFR3-like group
or a P53-like group. However, it is also possible that yet a third
genetic pathway is responsible for a portion of these tumors. Previous
work reviewed by Cote and Datar (17) suggests that RB and p16
and/or pARF alterations are mostly associated with the P53-mutant
UCCs and, thereby, are expected to be part of this pathway. However,
it is not yet clear whether these mutations occur before or after the
P53 event. The same holds true for other less frequently occurring
alterations. Thus far, no mutations, besides LOH for 9p/9q and other
chromosomes have been described to concur with FGFR3 mutations.
Therefore, additional investigations are required to place all markers
in the pathway model. Consequently, the arrow on the right in Fig. 3
signifies an increasing frequency of LOH and other genetic aberra-
tions from the top to the bottom.
The colorectal cancer model proposed by Fearon and Vogelstein
(20) is the prototype for the molecular evolution of cancer. The model
is presented as a linear model, in which inactivation of APC, mutation
of KRAS, inactivation of a gene on 18q, and inactivation of P53 occur
as sequential steps in the development from low-grade adenomas to
carcinoma. However, Smith et al. (21) recently showed that co-
occurrence of mutations in both KRAS and P53 in colorectal cancers
is extremely rare, and they suggest that these mutations, in fact, lie on
alternate pathways of colorectal tumor development. Thus, the route
to colorectal cancer seems to bifurcate after the initial APC step into
at least two alternative genetic pathways. This situation is similar to
the one that we describe for UCC in Fig. 3. In colorectal cancer, KRAS
mutations are overrepresented in Dukes C tumors, and, thereby, KRAS
may be a marker for tumor progression. The added value of the model
for UCC pathogenesis is that FGFR3 and P53 represent makers for
favorable and unfavorable disease, respectively. Together, these
markers characterize almost 80% of all primary tumors. The search
for mutations in other genes of both pathways may increase the
percentage of molecularly characterized tumors further and may fa-
cilitate a more complete molecular description of UCC as a possible
alternative for classical pathology (18). Moreover, the favorable
FGFR3 marker is a potential candidate to identify patients for whom
a less frequent follow-up is required, and this may help reduce the
costs of management for patients with UCC.
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